ACM
ABEO icon

AIGH Capital Management’s Abeona Therapeutics ABEO Stock Holding History

AIGH Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Buy
3,100,000
+1,100,000
+55% +$5.5M 1.89% 16
2025
Q4 		$10.5M Buy
+2,000,000
New +$10.1M 2.55% 14
2024
Q1 		– Sell
-787,769
Closed -$3.95M – 44
2023
Q4 		$3.95M Sell
787,769
-347,483
-31% -$1.53M 1.56% 25
2023
Q3 		$4.78M Buy
1,135,252
+496,278
+78% +$1.88M 2.26% 17
2023
Q2 		$2.58M Sell
638,974
-13,200
-2% -$46.2K 1.05% 24
2023
Q1 		$1.84M Hold
652,174
– – 0.68% 34
2022
Q4 		$2.01M Buy
652,174
+511,530
+364% +$1.91M 0.66% 32
2022
Q3 		$428K Buy
+140,644
New +$580K 0.13% 42
2022
Q2 		– Sell
-201,004
Closed -$1.58M – 48
2022
Q1 		$1.58M Buy
201,004
+155,513
+342% +$1.07M 0.39% 32
2021
Q4 		$383K Buy
+45,491
New +$836K 0.12% 47

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIGH Capital Management's ABEO Position: Q1 2026 in Review

AIGH Capital Management increased its Abeona Therapeutics (ABEO) stake by 55% in Q1 2026, buying an estimated $5.5M and bringing the position to 3,100,000 shares worth $13.9M. The position accounts for 1.89% of the portfolio, ranked #16.

AIGH Capital Management first reported a position in ABEO in Q4 2021 and has held it in 10 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • AIGH Capital Management held 3,100,000 shares of Abeona Therapeutics worth $13.9M as of Q1 2026.
  • AIGH Capital Management bought 1,100,000 Abeona Therapeutics shares in Q1 2026, an estimated $5.5M.
  • Abeona Therapeutics made up 1.89% of AIGH Capital Management's portfolio in Q1 2026, its #16 holding.
  • AIGH Capital Management first reported a position in Abeona Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.